| Ytd | 19.02% | |
| 1y | 34.53% |
| Open | 3.90 | Prev Close | 3.89 | Low | 3.89 | High | 4.32 | Mkt Cap | 762.21M |
| Vol | 2.04M | Avg Vol | 2.64M | EPS | -1.23 | P/E | N/A | Forward P/E | -3.96 |
| Beta | 2.67 | Short Ratio | 5.85 | Inst. Own | 44.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.27 | 200-d Avg | 3.94 | 1yr Est | 6.50 |
PRME News
Dow Jones gains 350 points, Iridium acquired by Rocket Lab for $8B, big stocks recording gains: Quid
Top Wall Street analysts upgraded Prime Medicine, Inc and Casey's General Stores Inc, and upgrad
HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to B
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst
Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ:PRME) with a Ou
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and an
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of d
Citigroup analyst Samantha Semenkow maintains Prime Medicine (NASDAQ:PRME) with a Neutral and low
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst
Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of d
Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral a
JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outpe
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans ---- Initial d
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-con
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.40) per share which missed the analyst
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and rai
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Med
Citizens Capital Markets analyst Silvan Tuerkcan reiterates Prime Medicine (NASDAQ:PRME) with a M
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and mai
JMP Securities analyst Silvan Tuerkcan initiates coverage on Prime Medicine (NASDAQ:PRME) with a
Guggenheim analyst Debjit Chattopadhyay reiterates Prime Medicine (NASDAQ:PRME) with a Buy and ma
Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and low
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which missed the analyst
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and